Mesa Science Associates and Bryn Pharma Announce Initial Study of a New Approach to Treating Anaphylaxis
On November 10, 2019, Mr. Michael Mesa, President, and CEO
of Mesa Science Associates (MSA), announced the presentation of a non-clinical
study regarding Nasal Administration of Epinephrine. The results were presented
by Kenneth Dretchen Ph.D., CSO and Principle Investigator at MSA. The study was
presented in a poster at the American College of Allergy, Asthma, and
Immunology (ACAAI) annual conference in Houston, Texas on November 10, 2019. The poster entitled, “Intranasal Effects on Pharmacokinetics
and Heart Rate in a Nasal Congestion Canine Model” is the first in a series of publications to be
presented by MSA that detail the results of non-clinical studies conducted to
support the concept of Nasal Administration of Epinephrine for patients
suffering from a severe allergic reaction, commonly known as anaphylaxis. MSA
and MRI Global of Kansas City, MO. collaborated on the study which was funded by
Bryn Pharma LLC. The study was conducted to determine the ability of
epinephrine to be absorbed through the nasal mucosa and to determine blood
levels and pharmacokinetic values when the drug is applied nasally to dogs that
have nasal congestion. The nasal congestion was induced by continuous exposure
to histamine throughout the test period. This study has shown that even with nasal
congestion present the nasal route of administration of epinephrine in canines
produce even higher plasma levels of the drug as compared to the intramuscular
route of administration.
The current therapy to treat an anaphylactic event is the administration
of epinephrine by intramuscular injection via an auto-injector. While this
treatment has shown to be effective, problems with auto-injectors include patient
concerns about needles that can lead to avoidance, delayed therapy, or even
injury at the injection site. Bryn Pharma, a North Carolina based company, is
developing a new cost-effective two-dose nasally administered therapy that has
the potential to mitigate most of the issues with autoinjector administration. The
device is a small compact unit that is needle-free and easy to carry in pockets
or purses. MSA is under contract to support the Bryn effort through commercial
launch.
Mesa Science Associates is a pharmaceutical product
development company located inside the Frederick Innovation and Technology
Center Inc. (FITCI) in Frederick MD. The
goal of the company is to provide technical and scientific expertise to
researchers from all aspects of the drug, drug delivery and product development
community, including researchers from the government, academia, and private
entities.
Written By:
Michael Mesa, CEO of Mesa Science Associates Inc. (MSA)
Share this news:
Business Development for Frederick!
For scientists and entrepreneurs who want tough love from proven growth fanatics to confidently take the next step.
Email Sign-Up
Get Connected! Stay up to date on FITCI Activities and Events.
Stay up to date on our newest products and services.
Your information is 100% safe. We hate spam too.
U.S. DEPARTMENT OF COMMERCE ANNOUNCES 51 “BUILD TO SCALE” GRANTS TOTALING $47 MILLIONTO FUEL INNOVATION AND TECH-BASED ECONOMIC DEVELOPMENT
Contact: EDA Public Affairs Department, (202) 482-4085
October 5, 2022
WASHINGTON – Today, U.S. Secretary of Commerce Gina Raimondo announced that the Department’s Economic Development Administration (EDA) is awarding 51 “Build to Scale” grants – totaling $47 million – to organizations that support technology entrepreneurs, catalyze innovation and fuel economic growth.
EDA’s “Build to Scale” program provides annual grants that aim to accelerate technology entrepreneurship by increasing inclusive access to entrepreneurial support and startup capital. The 2022 awardees will leverage an additional $48 million in matching funds from a variety of private and public sector sources. These EDA investments support advanced manufacturing, bioscience, clean energy and blue economy clusters in regions throughout the United States.
"Strengthening technology ecosystems are a critical key to the Biden Administration's efforts to build a stronger America,” said Secretary of Commerce Gina Raimondo. “Innovation and entrepreneurship have long been keys to American success and will continue to strengthen our collective economic and national security, as well as individual prosperity and well-being.”
"EDA is proud to partner with this year's 'Build to Scale' grantees as they invest in entrepreneurs and create equitable access to capital in their communities," said Assistant Secretary of Commerce for Economic Development Alejandra Y. Castillo. "These projects will give the next generation of industry-leading companies a seminal boost that will result in job creation and private investment – potentially transforming a regional economy and creating economic opportunity beyond what we can foresee.”
The 2022 Build to Scale program was comprised of two competitions––the Venture Challenge and the Capital Challenge. The Venture Challenge supports programs that enable high-growth technology entrepreneurship and foster inclusive access to proven entrepreneurship support models. The Capital Challenge increases access to capital in communities where risk capital is in short supply by providing operational support for early-stage investment funds, networks, and training programs that focus on both traditional and hybrid equity-based financing.
About the U.S. Economic Development Administration (www.eda.gov)
The mission of the U.S. Economic Development Administration (EDA) is to lead the federal economic development agenda by promoting competitiveness and preparing the nation's regions for growth and success in the worldwide economy. An agency within the U.S. Department of Commerce, EDA invests in communities and supports regional collaboration in order to create jobs for U.S. workers, promote American innovation, and accelerate long-term sustainable economic growth.
